Related Experiment Videos
Tumors after renal transplantation
R Schmidt1, D Stippel, T Schmitz-Rixen
1Department of Surgery, University of Cologne, Germany.
Urologia Internationalis
|January 1, 1996
Summary
Malignancies developed in 6.0% of renal transplant recipients. Cyclosporine immunosuppression increased cancer risk, necessitating routine post-transplant screenings for early detection.
Area of Science:
- Nephrology
- Oncology
- Transplantation Medicine
Background:
- Renal transplantation is a life-saving procedure.
- Organ transplant recipients face an increased risk of de novo malignancies.
- Immunosuppression is crucial but can contribute to cancer development.
Purpose of the Study:
- To investigate the incidence and types of malignancies following renal transplantation.
- To compare cancer development rates between different immunosuppression strategies.
Main Methods:
- Retrospective analysis of 633 renal graft recipients with >1 year graft function.
- Follow-up period averaged 67.6 months.
- Cancer incidence was analyzed in relation to immunosuppressive therapy (cyclosporine vs. conventional).
Main Results:
- 38 recipients (6.0%) developed de novo malignancies (skin, genitourinary, bronchial, breast, colon).
- Cancer incidence was significantly higher in the cyclosporine-treated group.
- 15 patients died, with a mean survival time of 7.7 months post-diagnosis.
Conclusions:
- Renal transplant recipients have a notable risk of developing de novo cancers.
- Cyclosporine-based immunosuppression is associated with a higher frequency of malignancies.
- Routine pre- and post-transplant screening is essential for early detection of cancers in these patients.